Drug intelligence / Profile preview

qianlietai

Development stage: Unknown
Lead developer: Guangxi Gufang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Qianlietai (前列泰颗粒) is a traditional Chinese medicine formulation in granule form, primarily used for the treatment of chronic prostatitis characterized by damp-heat and blood stasis syndromes. The product is indicated to clear heat, promote diuresis, activate blood circulation, and resolve masses. It is commonly prescribed for symptoms associated with chronic prostatitis in traditional Chinese medicine practice. The mechanism of action involves multiple herbal components that are believed to exert anti-inflammatory, diuretic, and microcirculation-improving effects according to TCM theory. Clinical studies have compared its efficacy with other TCM products for chronic prostatitis[9][10].

Brand names: 前列泰颗粒
Other names: Qianlietai granules

Beyond the preview

Go deeper on qianlietai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qianlietai.

Explore the full profile